Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma

BACKGROUND: RAS effector signaling pathways such as PI3K/mTOR and ERK are frequently dysregulated in glioblastoma. While small molecule targeted therapies against these pathways have appeared promising in preclinical studies, they have been disappointing in clinical trials due to toxicity and de nov...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurooncol Adv
Asıl Yazarlar: Schreck, Karisa C, Allen, Amy N, Wang, Jiawan, Pratilas, Christine A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Basic and Translational Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7668446/
https://ncbi.nlm.nih.gov/pubmed/33235998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa138
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller